Adverse Event Reporting & SAE Management

Communication with IRB/Regulators: End-to-End Compliance Framework for Global Clinical Trials Communication with IRB/Regulators: End-to-End Compliance Framework for Global Clinical Trials Effective communication with Institutional Review Boards (IRBs) and regulatory authorities is critical for the success of clinical trials. This article provides a comprehensive step-by-step tutorial on establishing a robust communication strategy to navigate the complexities…

Read More “Communication with IRB/Regulators: End-to-End Compliance Framework for Global Clinical Trials” »

Digital Tools and Automation to Streamline Communication with IRB/Regulators Digital Tools and Automation to Streamline Communication with IRB/Regulators The landscape of clinical trials is evolving rapidly, particularly in the domains of communication with Institutional Review Boards (IRBs) and regulatory authorities. As organizations like Amgen advance their clinical trials, including the integration of real-world evidence (RWE)…

Read More “Digital Tools and Automation to Streamline Communication with IRB/Regulators” »

Aligning Communication with IRB/Regulators With GCP, ICH E2A–E2F and Local Regulations In the domain of translational clinical research, effective communication with Institutional Review Boards (IRBs) and regulators is critical for the success of clinical trial operations. This article serves as a comprehensive guide, structured step-by-step, to navigate the complexities of aligning communication with regulatory bodies…

Read More “Aligning Communication with IRB/Regulators With GCP, ICH E2A–E2F and Local Regulations” »

Common Pitfalls in Communication with IRB/Regulators—and How to Avoid Regulatory Findings Effective communication with Institutional Review Boards (IRBs) and regulatory agencies is critical for the successful conduct of clinical research trials. Navigating the regulatory landscape can be challenging, particularly given the complexities and nuances involved in obtaining approvals, reporting changes, and maintaining compliance with evolving…

Read More “Common Pitfalls in Communication with IRB/Regulators—and How to Avoid Regulatory Findings” »

Case Studies: Communication with IRB/Regulators That Strengthened Safety Oversight Effective communication with Institutional Review Boards (IRBs) and regulatory agencies is essential for ensuring patient safety and regulatory compliance in clinical trials. As professionals in clinical operations, regulatory affairs, and medical affairs, understanding how to navigate these communications can significantly influence the efficacy of trial oversight….

Read More “Case Studies: Communication with IRB/Regulators That Strengthened Safety Oversight” »

KRIs, KPIs and Dashboards to Monitor Communication with IRB/Regulators Across Portfolios KRIs, KPIs and Dashboards to Monitor Communication with IRB/Regulators Across Portfolios Introduction to Key Risk Indicators (KRIs), Key Performance Indicators (KPIs), and Dashboards In clinical research, effectively monitoring communication with Institutional Review Boards (IRBs) and regulatory authorities is critical. This monitoring ensures compliance with…

Read More “KRIs, KPIs and Dashboards to Monitor Communication with IRB/Regulators Across Portfolios” »

Inspection-Ready Documentation Standards for Communication with IRB/Regulators Inspection-Ready Documentation Standards for Communication with IRB/Regulators Introduction Effective communication with Institutional Review Boards (IRB) and regulatory authorities is critical in the landscape of clinical trials, particularly when it concerns the standards for documentation. The nuances of these communications vary depending on the geographic region, including the US,…

Read More “Inspection-Ready Documentation Standards for Communication with IRB/Regulators” »

Training Investigators and Sites to Execute Communication with IRB/Regulators Reliably Training Investigators and Sites to Execute Communication with IRB/Regulators Reliably Introduction to Regulatory Communications in Clinical Trials Effective communication between investigators, clinical sites, and Institutional Review Boards (IRBs) is crucial for the successful execution of clinical trials, particularly in the context of bladder cancer clinical…

Read More “Training Investigators and Sites to Execute Communication with IRB/Regulators Reliably” »

Vendor and Partner Oversight Considerations in Communication with IRB/Regulators Vendor and Partner Oversight Considerations in Communication with IRB/Regulators The landscape of clinical research, particularly concerning metformin clinical trials, has brought to light the critical need for effective communication with Institutional Review Boards (IRBs) and regulatory bodies. A robust oversight mechanism over vendors and partners is…

Read More “Vendor and Partner Oversight Considerations in Communication with IRB/Regulators” »

Integrating Communication with IRB/Regulators With DSURs, PBRERs and Risk Management Plans Integrating Communication with IRB/Regulators With DSURs, PBRERs and Risk Management Plans In the intricate landscape of clinical trials, maintaining robust communication with Institutional Review Boards (IRBs) and regulatory authorities is paramount. This guide serves as a comprehensive tutorial for clinical operations, regulatory affairs, and…

Read More “Integrating Communication with IRB/Regulators With DSURs, PBRERs and Risk Management Plans” »